Dornase Alfa Administered to Patients With COVID-19 (DACOVID)

Nebulized In-line Endotracheal Dornase Alfa and Albuterol Administered to Mechanically Ventilated COVID-19 Patients: A Case Series

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04387786

Acronym

DACOVID

Enrollment

Registered

2020-05-14

Start date

2020-03-31

Completion date

2020-09-04

Last updated

2020-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19, Mechanical Ventilation

Brief summary

Mechanically ventilated patients with coronavirus disease 2019 (COVID-19) have a mortality of 24-53%, in part due to distal mucopurulent secretions interfering with ventilation. Dornase alfa is recombinant human DNase 1 and digests DNA in mucoid sputum. Nebulized dornase alfa is FDA-approved for cystic fibrosis treatment. DNA from neutrophil extracellular traps (NETs) contributes to the viscosity of mucopurulent secretions. NETs are found in the serum of patients with severe COVID-19, and targeting NETs reduces mortality in animal models of acute respiratory distress syndrome (ARDS). Thus, dornase alfa may be beneficial to patients with severe COVID-19-acting as a mucolytic and targeting NETs.

Detailed description

Demographic, clinical data, and outcomes were collected from the electronic medical records of five mechanically ventilated patients with COVID-19-including three requiring veno-venous extracorporeal membrane oxygenation (VV-ECMO)-treated with nebulized in-line endotracheal dornase alfa co-administered with albuterol (used to increase delivery to the alveoli), between March 31 and April 24, 2020. Data on tolerability and responses, including longitudinal values capturing respiratory function and inflammatory status, were analyzed.

Interventions

DRUGDornase Alfa

nebulized in-line endotracheal dornase alfa co-administered with albuterol

Study design

Observational model

CASE_ONLY

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 85 Years

Healthy volunteers

Inclusion criteria

* mechanically ventilated patients with COVID-19

Exclusion criteria

* healthy, non-ventilated

Design outcomes

Primary

Measure	Time frame	Description
Number of participants discharged from the intensive care unit (ICU)	2 months	discharge from ICU will be determined from the enterprise health record reporting database
Number of participants who survived COVID-19	2-4 months	survival will be determined from the enterprise health record reporting database

Secondary

Measure	Time frame	Description
Mean change in FiO2	2 months	fraction of inspired oxygen requirements will be measured

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026